TY - JOUR
T1 - Molecular classification improves risk assessment in adult BCR-ABL1–negative B-ALL
AU - Paietta, Elisabeth
AU - Roberts, Kathryn G.
AU - Wang, Victoria
AU - Gu, Zhaohui
AU - Buck, Georgina A.N.
AU - Pei, Deqing
AU - Cheng, Cheng
AU - Levine, Ross L.
AU - Abdel-Wahab, Omar
AU - Cheng, Zhongshan
AU - Wu, Gang
AU - Qu, Chunxu
AU - Shi, Lei
AU - Pounds, Stanley
AU - Willman, Cheryl L.
AU - Harvey, Richard
AU - Racevskis, Janis
AU - Barinka, Jan
AU - Zhang, Yanming
AU - Dewald, Gordon W.
AU - Ketterling, Rhett P.
AU - Alejos, David
AU - Lazarus, Hillard M.
AU - Luger, Selina M.
AU - Foroni, Letizia
AU - Patel, Bela
AU - Fielding, Adele K.
AU - Melnick, Ari
AU - Marks, David I.
AU - Moorman, Anthony V.
AU - Wiernik, Peter H.
AU - Rowe, Jacob M.
AU - Tallman, Martin S.
AU - Goldstone, Anthony H.
AU - Mullighan, Charles G.
AU - Litzow, Mark R.
N1 - Publisher Copyright:
© 2021 American Society of Hematology
PY - 2021/9/16
Y1 - 2021/9/16
N2 - Genomic classification has improved risk assignment of pediatric, but not adult B-lineage acute lymphoblastic leukemia (B-ALL). The international UKALLXII/ECOG-ACRIN E2993 (#NCT00002514) trial accrued 1229 adolescent/adult patients with BCR-ABL1− B-ALL (aged 14 to 65 years). Although 93% of patients achieved remission, 41% relapsed at a median of 13 months (range, 28 days to 12 years). Five-year overall survival (OS) was 42% (95% confidence interval, 39, 44). Transcriptome sequencing, gene expression profiling, cytogenetics, and fusion polymerase chain reaction enabled genomic subtyping of 282 patient samples, of which 264 were eligible for trial, accounting for 64.5% of E2993 patients. Among patients with outcome data, 29.5% with favorable outcomes (5-year OS 65% to 80%) were deemed standard risk (DUX4-rearranged [9.2%], ETV6-RUNX1/-like [2.3%], TCF3-PBX1 [6.9%], PAX5 P80R [4.1%], high-hyperdiploid [6.9%]); 50.2% had high-risk genotypes with 5-year OS of 0% to 27% (Ph-like [21.2%], KMT2A-AFF1 [12%], low-hypodiploid/near-haploid [14.3%], BCL2/MYC-rearranged [2.8%]); 20.3% had intermediate-risk genotypes with 5-year OS of 33% to 45% (PAX5alt [12.4%], ZNF384/-like [5.1%], MEF2D-rearranged [2.8%]). IKZF1 alterations occurred in 86% of Ph-like, and TP53 mutations in patients who were low-hypodiploid (54%) and BCL2/MYC-rearranged (33%) but were not independently associated with outcome. Of patients considered high risk based on presenting age and white blood cell count, 40% harbored subtype-defining genetic alterations associated with standard- or intermediate-risk outcomes. We identified distinct immunophenotypic features for DUX4-rearranged, PAX5 P80R, ZNF384-R/-like, and Ph-like genotypes. These data in a large adult B-ALL cohort treated with a non–risk-adapted approach on a single trial show the prognostic importance of genomic analyses, which may translate into future therapeutic benefits.
AB - Genomic classification has improved risk assignment of pediatric, but not adult B-lineage acute lymphoblastic leukemia (B-ALL). The international UKALLXII/ECOG-ACRIN E2993 (#NCT00002514) trial accrued 1229 adolescent/adult patients with BCR-ABL1− B-ALL (aged 14 to 65 years). Although 93% of patients achieved remission, 41% relapsed at a median of 13 months (range, 28 days to 12 years). Five-year overall survival (OS) was 42% (95% confidence interval, 39, 44). Transcriptome sequencing, gene expression profiling, cytogenetics, and fusion polymerase chain reaction enabled genomic subtyping of 282 patient samples, of which 264 were eligible for trial, accounting for 64.5% of E2993 patients. Among patients with outcome data, 29.5% with favorable outcomes (5-year OS 65% to 80%) were deemed standard risk (DUX4-rearranged [9.2%], ETV6-RUNX1/-like [2.3%], TCF3-PBX1 [6.9%], PAX5 P80R [4.1%], high-hyperdiploid [6.9%]); 50.2% had high-risk genotypes with 5-year OS of 0% to 27% (Ph-like [21.2%], KMT2A-AFF1 [12%], low-hypodiploid/near-haploid [14.3%], BCL2/MYC-rearranged [2.8%]); 20.3% had intermediate-risk genotypes with 5-year OS of 33% to 45% (PAX5alt [12.4%], ZNF384/-like [5.1%], MEF2D-rearranged [2.8%]). IKZF1 alterations occurred in 86% of Ph-like, and TP53 mutations in patients who were low-hypodiploid (54%) and BCL2/MYC-rearranged (33%) but were not independently associated with outcome. Of patients considered high risk based on presenting age and white blood cell count, 40% harbored subtype-defining genetic alterations associated with standard- or intermediate-risk outcomes. We identified distinct immunophenotypic features for DUX4-rearranged, PAX5 P80R, ZNF384-R/-like, and Ph-like genotypes. These data in a large adult B-ALL cohort treated with a non–risk-adapted approach on a single trial show the prognostic importance of genomic analyses, which may translate into future therapeutic benefits.
UR - http://www.scopus.com/inward/record.url?scp=85113347637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113347637&partnerID=8YFLogxK
U2 - 10.1182/blood.2020010144
DO - 10.1182/blood.2020010144
M3 - Article
C2 - 33895809
AN - SCOPUS:85113347637
SN - 0006-4971
VL - 138
SP - 948
EP - 958
JO - Blood
JF - Blood
IS - 11
ER -